CIPYP   05508
CENTRO DE INVESTIGACIONES SOBRE PORFIRINAS Y PORFIRIAS
Unidad Ejecutora - UE
artículos
Título:
Identification of CYP3A5 and CYP2B6 Polymorphisms in Porphrya Cutanea Tarda assocoates to human Inmunodeficiency virus
Autor/es:
LAVANDERA, JIMENA; PARERA, VICTORIA; ROSSETTI MARÍA VICTORIA; BATLLE, ALCIRA; BUZALEH, ANA MARIA
Revista:
JOURNAL OF CLINICAL AND EXPERIMENTAL DERMATOLOGY RESEARCH
Editorial:
OMICS Publishing Group
Referencias:
Año: 2011 vol. S p. 1 - 5
ISSN:
2155-9554
Resumen:
To date, few or no data concerning the prevalence of polymorphisms in drug metabolism genes of antiretroviral
drugs have been reported in the Argentinean population or in porphyric individuals worldwide. The purpose of the
current investigation was to determine whether interindividual differences in cytochrome P450 3A5 (CYP3A) and
2B6 (CYP2B6) genes could influence the triggering of Porphyria Cutanea Tarda (PCT) in subjects with human
immunodeficiency virus (HIV) after antiretroviral exposure.
A total of 141 subjects, 60 control volunteers and 81 unrelated individuals with PCT were included in the study. In
the porphyric group, 21 individuals were HIV positive. To evaluate the presence of the alleles CYP3A5*3, CYP3A5*6
and CYP2B6*6 a polymerase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP)
analysis was performed.
The frequencies of CYP3A5*3 were 0.91 in control group, 0.89 in PCT patients and 0.89 in PCT-HIV. CYP2B6*6
frequencies were 0.31 in control group, 0.34 in PCT group and 0.30 in PCT-HIV group. We have shown that the
allelic frequencies of CYP3A5*3 or CYP2B6*6 in our population were similar to those reported for other Caucasian
populations.
Although, we have not found significant differences in polymorphisms of CYP3A5 and CYP2B6 between the
different groups analyzed, there are an enormous number of biological variables that may influence antiretroviral
treatment, like other genetic polymorphisms of phase I or phase II enzymes, or transporters like multidrug resistance
transporter gene (MDR1), which can contribute to antiretroviral drug toxicities and response or even it is possible that
the PCT-HIV association has more than one factor responsible for the onset of PCT symptoms.